Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
KRAS alleles: the devil is in the detail
KM Haigis - Trends in cancer, 2017 - cell.com
KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …
Treatment of metastatic colorectal cancer: ASCO guideline
PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …
Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2021 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
J van de Haar, X Ma, SN Ooft, PW van der Helm… - Nature Medicine, 2023 - nature.com
Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole …
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole …
[HTML][HTML] Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis… - Annals of …, 2018 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …
Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, L Cederquist, E Chan… - Journal of the National …, 2017 - jnccn.org
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …
therapy in metastatic disease. Considerations for treatment selection among 32 different …
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
JC Jones, LA Renfro, HO Al-Shamsi… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Molecular diagnostic testing has become an integral part of the evaluation of
patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next …
patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next …
[HTML][HTML] The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients
M Van den Eynde, B Mlecnik, G Bindea, T Fredriksen… - Cancer cell, 2018 - cell.com
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are
homogeneous within a patient. We quantified immune cell types of 603 whole-slide …
homogeneous within a patient. We quantified immune cell types of 603 whole-slide …
[HTML][HTML] A perspective on anti-EGFR therapies targeting triple-negative breast cancer
K Nakai, MC Hung, H Yamaguchi - American journal of cancer …, 2016 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …